JNJJanssen Research & Development, LLCRunning, no new patients
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
Castration-Resistant Prostatic Cancer
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 765 (final count)
- Started
- Jan 25, 2019
- Main results expected
- Oct 8, 2021
- Fully finished
- Dec 31, 2027
- Results posted
- Oct 4, 2023
What counts as success
The trial's main goal(s), called the “primary outcome.”
Cohort 1: Radiographic Progression-Free Survival (rPFS) as Assessed by Blinded Independent Central Review (BICR)
Measured over: Up to 32 months
Cohort 1 Breast Cancer Gene (BRCA) Subgroup: Radiographic Progression-Free Survival (rPFS) as Assessed by Blinded Independent Central Review (BICR)
Measured over: Up to 32 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03748641 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC